Contrast-enhanced ultrasonography–CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome

医学 射频消融术 放射科 经皮 烧蚀 超声造影 肝肿瘤 肝细胞癌 超声波 超声科 内科学
作者
Yuna Lee,Jeong Hee Yoon,Seung-Wan Han,Ijin Joo,Jeong Min Lee
出处
期刊:Cancer Imaging [BioMed Central]
卷期号:24 (1)
标识
DOI:10.1186/s40644-023-00650-y
摘要

Percutaneous radiofrequency ablation (RFA) is pivotal for treating small malignant liver tumors, but tumors often remain inconspicuous on B-mode ultrasound (US). This study evaluates the potential of CEUS-CT/MRI fusion imaging (FI) to improve tumor visibility and the associated RFA outcomes for small (≤ 3 cm) malignant liver tumors that were inconspicuous on US.Between January 2019 and April 2021, a prospective study enrolled 248 patients with liver malignancies (≤ 3 cm) that were poorly visible on B-mode US. Tumor visibility and ablation feasibility were assessed using B-mode US, US-CT/MRI FI, and CEUS-CT/MRI FI, and graded on a 4-point scale. CEUS was employed post-registration of US and CT/MRI images, utilizing either SonoVue or Sonazoid. Comparisons between US-based and CEUS-based fusion visibility and feasibility scores were undertaken using the Friedman test. Moreover, rates of technical success, technique efficacy, local tumor progression (LTP), and major complications were assessed.The cohort included 223 hepatocellular carcinomas (HCCs) (89.9%) and 23 metastases (9.3%), with an average tumor size of 1.6 cm. CEUS-CT/MRI FI demonstrated a significant advantage in tumor visibility (3.4 ± 0.7 vs. 1.9 ± 0.6, P < 0.001) and technical feasibility (3.6 ± 0.6 vs. 2.9 ± 0.8, P < 0.001) compared to US-FI. In 85.5% of patients, CEUS addition to US-FI ameliorated tumor visibility. Technical success was achieved in 99.6% of cases. No severe complications were reported. One and two-year post CEUS-CT/MRI FI-guided RFA estimates for LTP were 9.3% and 10.9%, respectively.CEUS-CT/MRI FI significantly improves the visualization of tumors not discernible on B-mode US, thus augmenting percutaneous RFA success and delivering improved therapeutic outcomes.ClinicalTrials.gov, NCT05445973. Registered 17 June 2022 - Retrospectively registered, http://clinicaltrials.gov/study/NCT05445973?id=NCT05445973&rank=1 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xin发布了新的文献求助10
1秒前
充电宝应助CucRuotThua采纳,获得10
1秒前
深情安青应助健忘的伟宸采纳,获得10
1秒前
yhy发布了新的文献求助10
2秒前
乔凌云发布了新的文献求助10
2秒前
3秒前
所所应助严惜采纳,获得10
6秒前
爱学术的LaoD完成签到,获得积分10
6秒前
7秒前
桐桐应助科研通管家采纳,获得10
7秒前
Lucas应助科研通管家采纳,获得10
7秒前
molihuakai应助科研通管家采纳,获得10
8秒前
JamesPei应助科研通管家采纳,获得10
8秒前
彭于晏应助科研通管家采纳,获得50
8秒前
8秒前
英俊的铭应助科研通管家采纳,获得10
8秒前
充电宝应助科研通管家采纳,获得10
8秒前
9秒前
9秒前
Phucgialam发布了新的文献求助10
9秒前
9秒前
CipherSage应助科研通管家采纳,获得10
9秒前
9秒前
深情安青应助科研通管家采纳,获得10
9秒前
ZS-完成签到 ,获得积分10
9秒前
10秒前
siijjfjjf完成签到 ,获得积分10
12秒前
852应助义气的胡采纳,获得10
13秒前
qwewyq12307完成签到,获得积分10
15秒前
16秒前
s1144完成签到,获得积分10
16秒前
坚强三德完成签到 ,获得积分10
17秒前
17秒前
NiaoJiang完成签到,获得积分10
18秒前
孔wj完成签到,获得积分10
19秒前
酷波er应助艺阳采纳,获得10
19秒前
蓝天发布了新的文献求助10
19秒前
严惜发布了新的文献求助10
21秒前
英姑应助Rouga采纳,获得10
22秒前
许可证发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
晶种分解过程与铝酸钠溶液混合强度关系的探讨 8888
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
The formation of Australian attitudes towards China, 1918-1941 640
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6430148
求助须知:如何正确求助?哪些是违规求助? 8246246
关于积分的说明 17536216
捐赠科研通 5486401
什么是DOI,文献DOI怎么找? 2895798
邀请新用户注册赠送积分活动 1872184
关于科研通互助平台的介绍 1711723